MX2016012447A - Formulaciones de factor ix liofilizadas. - Google Patents
Formulaciones de factor ix liofilizadas.Info
- Publication number
- MX2016012447A MX2016012447A MX2016012447A MX2016012447A MX2016012447A MX 2016012447 A MX2016012447 A MX 2016012447A MX 2016012447 A MX2016012447 A MX 2016012447A MX 2016012447 A MX2016012447 A MX 2016012447A MX 2016012447 A MX2016012447 A MX 2016012447A
- Authority
- MX
- Mexico
- Prior art keywords
- fix
- polypeptide
- formulations
- present
- factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mechanical Engineering (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención provee, entre otras cosas, formulaciones pre- liofilización, formulaciones reconstituidas y formulaciones de polvo liofilizado que comprenden un polipéptido de Factor IX (FIX). La presente invención proporciona también métodos de liofilización para producir un polvo liofilizado que comprende un polipéptido de FIX. La presente invención se refiere a una formulación pre-liofilización que comprende: (a) un polipéptido (FIX) de Factor IX que tiene actividad de coagulación FIX; (b) un agente amortiguador; (c) un agente estabilizante; (d) un agente espesante; y (e) un tensioactivo, donde la formulación tiene un volumen de relleno menor que alrededor de 5 mL y donde cada uno de (a) - (e) se encuentran en una cantidad por vial (mg/vial) suficiente para permitir (1) mejor estabilidad del polipéptido de FIX al liofilizarse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461969801P | 2014-03-24 | 2014-03-24 | |
PCT/US2015/022141 WO2015148444A1 (en) | 2014-03-24 | 2015-03-24 | Lyophilized factor ix formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016012447A true MX2016012447A (es) | 2017-01-06 |
Family
ID=54196282
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012447A MX2016012447A (es) | 2014-03-24 | 2015-03-24 | Formulaciones de factor ix liofilizadas. |
MX2021012939A MX2021012939A (es) | 2014-03-24 | 2016-09-23 | Formulaciones de factor ix liofilizadas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012939A MX2021012939A (es) | 2014-03-24 | 2016-09-23 | Formulaciones de factor ix liofilizadas. |
Country Status (17)
Country | Link |
---|---|
US (2) | US10772942B2 (es) |
EP (1) | EP3123090A4 (es) |
JP (4) | JP7058940B2 (es) |
KR (1) | KR102385372B1 (es) |
AR (1) | AR099838A1 (es) |
AU (3) | AU2015236340B2 (es) |
BR (1) | BR112016021777A2 (es) |
CA (1) | CA2943034C (es) |
CL (1) | CL2016002386A1 (es) |
EA (2) | EA202092926A3 (es) |
IL (3) | IL247869B (es) |
MA (1) | MA39779A (es) |
MX (2) | MX2016012447A (es) |
PH (1) | PH12016501877A1 (es) |
SG (3) | SG10201808249VA (es) |
TW (1) | TWI700101B (es) |
WO (1) | WO2015148444A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
MX2016012447A (es) | 2014-03-24 | 2017-01-06 | Biogen Ma Inc | Formulaciones de factor ix liofilizadas. |
BR112020000592A2 (pt) * | 2017-07-11 | 2020-07-14 | Universal Stabilization Technologies, Inc. | método para conservar materiais biológicos |
CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
CN115867307A (zh) * | 2020-05-11 | 2023-03-28 | 奥克梅斯制药爱尔兰有限公司 | Il-2融合多肽组合物以及其制备和使用方法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
DK0461200T3 (da) | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
EP1652534A3 (en) * | 1992-10-02 | 2007-05-02 | Genetics Institute, LLC | Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer |
DE4405426A1 (de) | 1994-02-21 | 1995-08-24 | Boehringer Mannheim Gmbh | Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
IN184589B (es) | 1996-10-16 | 2000-09-09 | Alza Corp | |
JP2001151694A (ja) | 1999-09-17 | 2001-06-05 | Takeda Chem Ind Ltd | タンパク質粉体の製造法 |
EP1219298A4 (en) | 1999-09-17 | 2003-06-11 | Takeda Chemical Industries Ltd | PROCESS FOR PRODUCING PROTEIN POWDER |
US7091321B2 (en) | 2000-02-11 | 2006-08-15 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
WO2002040544A2 (en) | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
RU2004110239A (ru) | 2001-09-04 | 2005-10-20 | Мерк Патент ГмбХ (DE) | Модифицированный фактор ix |
EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
JP2005060378A (ja) | 2003-07-28 | 2005-03-10 | Yamanouchi Pharmaceut Co Ltd | 生理活性蛋白質含有凍結乾燥製剤 |
US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
WO2005089712A1 (en) | 2004-03-04 | 2005-09-29 | Wyeth | Lyophilization method to improve excipient crystallization |
WO2006029467A1 (en) * | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
CN101124331B (zh) | 2004-11-12 | 2013-04-24 | 拜尔健康护理有限责任公司 | Fvⅲ的位点定向修饰 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2007014073A2 (en) | 2005-07-22 | 2007-02-01 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
WO2007044616A2 (en) * | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
EP1942868B2 (en) * | 2005-11-01 | 2023-10-04 | Wyeth LLC | Sodium chloride solution for drug reconstitution or dilution |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
HUE042402T2 (hu) | 2006-04-04 | 2019-06-28 | Chiesi Farm Spa | Eljárás polipeptid töményítésére |
EP2423307A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
US8015841B2 (en) * | 2006-09-08 | 2011-09-13 | Praxair Technology, Inc. | Cryogenic refrigeration system for lyophilization |
US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
EP2209487A4 (en) | 2007-10-15 | 2012-06-20 | Univ North Carolina | VARIANTS OF HUMAN FACTOR IX WITH EXTENDED HALF-TIME |
KR20100110799A (ko) | 2007-12-27 | 2010-10-13 | 백스터 인터내셔널 인코포레이티드 | 화학적으로 변형된 제 9 인자 |
KR20110015551A (ko) | 2008-04-16 | 2011-02-16 | 바이엘 헬스케어 엘엘씨 | 제ix인자의 부위-지정 변형 |
AU2009244633A1 (en) | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified Factor IX polypeptides and uses thereof |
EP2268807A2 (en) | 2008-04-21 | 2011-01-05 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
CA2729972C (en) | 2008-08-05 | 2018-11-20 | Wyeth Llc | Lyophilization above collapse |
BRPI0918988A2 (pt) | 2008-09-24 | 2015-12-01 | Stabilitech Ltd | métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina. |
AU2010263058A1 (en) | 2009-06-18 | 2012-01-12 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
KR20140017480A (ko) * | 2010-07-09 | 2014-02-11 | 바이오겐 이데크 헤모필리아 인코포레이티드 | 인자 ix 폴리펩티드 및 이들의 사용 방법 |
ES2561878T3 (es) | 2010-09-30 | 2016-03-01 | Toyama Chemical Co., Ltd. | Sal de meglumina de 6-fluoro-3-hidroxi-2-pirazinacarboxamida |
EP2672986B1 (en) | 2011-02-09 | 2020-03-18 | GlaxoSmithKline LLC | Lyophilized formulations |
AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
TWI750197B (zh) * | 2012-09-25 | 2021-12-21 | 美商百歐維拉提夫治療公司 | Fix多肽的應用 |
SG10201707600XA (en) * | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
MX2016012447A (es) * | 2014-03-24 | 2017-01-06 | Biogen Ma Inc | Formulaciones de factor ix liofilizadas. |
-
2015
- 2015-03-24 MX MX2016012447A patent/MX2016012447A/es unknown
- 2015-03-24 EA EA202092926A patent/EA202092926A3/ru unknown
- 2015-03-24 EA EA201691807A patent/EA038573B1/ru unknown
- 2015-03-24 CA CA2943034A patent/CA2943034C/en active Active
- 2015-03-24 TW TW104109389A patent/TWI700101B/zh active
- 2015-03-24 SG SG10201808249VA patent/SG10201808249VA/en unknown
- 2015-03-24 JP JP2016558751A patent/JP7058940B2/ja active Active
- 2015-03-24 US US15/128,951 patent/US10772942B2/en active Active
- 2015-03-24 SG SG10201913735SA patent/SG10201913735SA/en unknown
- 2015-03-24 KR KR1020167028692A patent/KR102385372B1/ko active IP Right Grant
- 2015-03-24 EP EP15769411.8A patent/EP3123090A4/en active Pending
- 2015-03-24 WO PCT/US2015/022141 patent/WO2015148444A1/en active Application Filing
- 2015-03-24 MA MA039779A patent/MA39779A/fr unknown
- 2015-03-24 SG SG11201607642RA patent/SG11201607642RA/en unknown
- 2015-03-24 AU AU2015236340A patent/AU2015236340B2/en not_active Withdrawn - After Issue
- 2015-03-24 BR BR112016021777A patent/BR112016021777A2/pt active Search and Examination
- 2015-03-25 AR ARP150100880A patent/AR099838A1/es unknown
-
2016
- 2016-09-18 IL IL247869A patent/IL247869B/en active IP Right Grant
- 2016-09-22 CL CL2016002386A patent/CL2016002386A1/es unknown
- 2016-09-23 MX MX2021012939A patent/MX2021012939A/es unknown
- 2016-09-23 PH PH12016501877A patent/PH12016501877A1/en unknown
-
2020
- 2020-01-26 IL IL272257A patent/IL272257B/en active IP Right Grant
- 2020-02-03 JP JP2020016131A patent/JP2020063313A/ja active Pending
- 2020-04-30 AU AU2020202863A patent/AU2020202863B2/en active Active
- 2020-08-17 US US16/995,173 patent/US20210069307A1/en active Pending
-
2021
- 2021-03-02 IL IL281197A patent/IL281197B/en unknown
-
2022
- 2022-01-20 JP JP2022007013A patent/JP2022044689A/ja active Pending
- 2022-08-10 AU AU2022215218A patent/AU2022215218A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033771A patent/JP2024053015A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012939A (es) | Formulaciones de factor ix liofilizadas. | |
PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
GEP201706734B (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
MX2020009878A (es) | Composiciones farmaceuticas en polvo seco estables al calor y metodos. | |
EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
MY150613A (en) | Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses | |
MX2019003716A (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
EA200870264A1 (ru) | Композиция антител | |
EP4257152A3 (en) | Apelin polypeptides | |
PH12019550084A1 (en) | Oligosaccharides for flavour generation | |
WO2015058173A8 (en) | Stable solid units and methods of making the same | |
TW200630118A (en) | Stabilized freeze-dried formulation for cephalosporin derivatives | |
MX2020007945A (es) | Proteinas f del rsv estabilizadas y usos de las mismas. | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
PH12018500458A1 (en) | Vlp stabilized vaccine compositions | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2017009289A (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
PH12018500675A1 (en) | Stable live attenuated recombinant dengue vaccine | |
MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
MX2016012870A (es) | Formulaciones de factor viii estables con bajo tenor de azucar - glicina. | |
WO2018085551A3 (en) | Formulations of pegylated arginine deiminase | |
GR1008818B (el) | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |